Cardioxyl Pharmaceuticals
Founded Year
2005Stage
Acquired | AcquiredTotal Raised
$66.55MValuation
$0000About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is a biopharmaceutical company. It develops therapeutic agents for the treatment of cardiovascular disease. It provides medication for the treatment of acute decompensated heart failure. The company was founded in 2005 and is based in Towson, Maryland. In 2015, Cardioxyl Pharmaceuticals was acquired by Bristol-Myers Squibb.
Missing: Cardioxyl Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cardioxyl Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cardioxyl Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cardioxyl Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
1,568 items
Cardioxyl Pharmaceuticals Patents
Cardioxyl Pharmaceuticals has filed 41 patents.
The 3 most popular patent topics include:
- Amines
- Carboxylic acids
- Cardiac arrhythmia
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/31/2020 | 4/19/2022 | Sulfonamides, Lactams, Hydrogen compounds, Amines, Hepatotoxins | Grant |
Application Date | 1/31/2020 |
|---|---|
Grant Date | 4/19/2022 |
Title | |
Related Topics | Sulfonamides, Lactams, Hydrogen compounds, Amines, Hepatotoxins |
Status | Grant |
Latest Cardioxyl Pharmaceuticals News
Jan 15, 2017
Cardioxyl Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 15:39 EST 15 Jan 2017 | BioPortfolio Reports Home » Topics » Biopharmaceuticals » Latest News » Cardioxyl Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 Summary Cardioxyl Pharmaceuticals Inc Cardioxyl is a clinical stage biopharmaceutical company involved in developing therapies for the treatment of cardiovascular diseases. It focuses on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist. Cardioxyl's pipeline product portfolio includes ADHF CXL1427, CHF and PAH . The company's other product CXL1020 is a nitroxyl donor compound used for treating acute decompensated heart failure and chronic heart failure. Cardioxyl's nitroxyl HNO chemistry platform technology is a drug discovery platform used in preclinical testing and in a Phase IIa human proof of concept study. Cardioxyl is headquartered in Chapel Hill, North Carolina, the US. Cardioxyl Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Cardioxyl Pharmaceuticals Frequently Asked Questions (FAQ)
When was Cardioxyl Pharmaceuticals founded?
Cardioxyl Pharmaceuticals was founded in 2005.
Where is Cardioxyl Pharmaceuticals's headquarters?
Cardioxyl Pharmaceuticals's headquarters is located at 40 York Road, Suite 501 , Towson.
What is Cardioxyl Pharmaceuticals's latest funding round?
Cardioxyl Pharmaceuticals's latest funding round is Acquired.
How much did Cardioxyl Pharmaceuticals raise?
Cardioxyl Pharmaceuticals raised a total of $66.55M.
Who are the investors of Cardioxyl Pharmaceuticals?
Investors of Cardioxyl Pharmaceuticals include Bristol-Myers Squibb, New Enterprise Associates, Aurora Funds, OrbiMed Advisors and Osage University Partners.
Who are Cardioxyl Pharmaceuticals's competitors?
Competitors of Cardioxyl Pharmaceuticals include Molmed, Arcadia Biosciences, Zevra Therapeutics, Larimar Therapeutics, Regado Biosciences and 12 more.
Compare Cardioxyl Pharmaceuticals to Competitors
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.
Kaperio is a biopharmaceutical company focused on cardiovascular disease.
Efficas is a biotechnology company focused on the discovery and rapid development of nutritional bioactives with clinically-proven efficacy for the management of human and animal health. Efficas' lead product will be a product derived from an edible fruit to assist in the control of atopic dermatitis.
InsectiGen, Inc. is a biotechnology company focused on discovery and development of biopesticides. Founded by Clifton Baile, PhD and Michael Adang PhD, InsectiGen has licensed IP from the University of Georgia associated with modified proteins form the intestine of insects that enhance natural insecticides produced by Bacillus thuringensis (Bt).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.